Key takeaways
- Semaglutide is a modified version of the hormone GLP-1, with 94% sequence homology to human GLP-1 according to its US label, and a C-18 fatty diacid side chain that binds albumin, a blood protein.
- Novo Nordisk sells it as Ozempic, Rybelsus and Wegovy. FDA first approved it as Ozempic in December 2017; the latest uses added in the US are kidney and cardiovascular outcomes in type 2 diabetes with chronic kidney disease (January 2025), the liver disease MASH (August 2025, accelerated approval) and cardiovascular risk in type 2 diabetes for Rybelsus (October 2025).
- Every US semaglutide label carries a boxed warning: in rodents semaglutide causes thyroid C-cell tumours, and whether it does so in humans is unknown. The labels also warn of pancreatitis, gallbladder disease, kidney injury and severe gastrointestinal reactions.
- FDA declared the US semaglutide shortage resolved on 21 February 2025. Its grace period for compounded copies ended for pharmacies after a court ruling in April 2025, and for outsourcing facilities on 22 May 2025.
- FDA says companies selling semaglutide “falsely labeled ‘for research purposes’” sold unapproved drugs illegally, and it announced seizures of counterfeit Ozempic in December 2023, April 2025 and December 2025.
01What is semaglutide?
Semaglutide is a modified version of GLP-1 (glucagon-like peptide-1), a hormone the body releases after eating. Its US label calls it a GLP-1 analogue with 94% sequence homology to human GLP-1 that “selectively binds to and activates the GLP-1 receptor”.
What was changed. A C-18 fatty diacid, attached through a spacer to the lysine at position 26, lets the molecule bind albumin, a blood protein. A change at position 8 protects it from the enzyme DPP-4, and a minor change at position 34 makes sure only one fatty diacid attaches. The peptide backbone is made by yeast fermentation. How it differs from tirzepatide: semaglutide vs tirzepatide.
| Question | Semaglutide |
|---|---|
| What it is | A GLP-1 receptor agonist; formula C187H291N45O59, 4113.58 g/mol (US label) |
| Maker and brands | Novo Nordisk: Ozempic, Rybelsus and Wegovy; in the EU also Kayshild |
| Status | Prescription medicine in the US and the UK; centrally authorised in the EU; Schedule 4 (Prescription Only Medicine) in Australia |
| Boxed warning (US) | Thyroid C-cell tumours in rodents; whether this happens in humans is unknown |
| Sport | On WADA’s 2027 Monitoring Program; not named on the 2027 Prohibited List |
Research-grade material sold as “semaglutide” is not Ozempic, Rybelsus or Wegovy. Nothing on this page describes it.
02Where is semaglutide approved, and for what?
Regulators approve products, not molecules. Dates and uses come from each regulator’s records, checked on 18 November 2026.
| Market | Products | What the labels cover |
|---|---|---|
| United States | Ozempic (5 Dec 2017), Rybelsus (20 Sep 2019; its label now also covers Ozempic tablets), Wegovy (4 Jun 2021), Wegovy tablets (22 Dec 2025) | Blood sugar control in type 2 diabetes (Ozempic, Rybelsus). Lower risk of cardiovascular death, heart attack or stroke in type 2 diabetes: with established cardiovascular disease, Ozempic (16 Jan 2020); at high risk of these events, Rybelsus (17 Oct 2025). Kidney outcomes in type 2 diabetes with chronic kidney disease: Ozempic (28 Jan 2025). Reducing excess body weight: Wegovy, adults (2021) and ages 12 and older (23 Dec 2022). Lower cardiovascular risk in adults with cardiovascular disease and obesity or overweight: Wegovy (8 Mar 2024). MASH, a liver disease, with moderate to advanced fibrosis: Wegovy (15 Aug 2025, accelerated approval). The adolescent and MASH uses are on the label for the original Wegovy product, not for Wegovy tablets |
| European Union | Ozempic (8 Feb 2018), Rybelsus (3 Apr 2020), Wegovy (6 Jan 2022), Kayshild (26 Mar 2026) | Ozempic and Rybelsus: type 2 diabetes. Wegovy: weight management in adults and adolescents 12 and older, with its cardiovascular trial results in the product information. Kayshild: MASH with moderate to advanced fibrosis, conditional approval |
| United Kingdom | Ozempic, Rybelsus, Wegovy | Ozempic and Rybelsus: type 2 diabetes. Wegovy: weight management in adults and adolescents; lower cardiovascular risk in adults with established cardiovascular disease and a BMI of 27 or more (23 Jul 2024); MASH (3 Jul 2026, conditional) |
| Australia | Ozempic (on the ARTG 28 Aug 2019), Wegovy | Ozempic: type 2 diabetes. Wegovy extended to adolescents 12 and older (29 Feb 2024). Semaglutide is in Schedule 4 of the Poisons Standard October 2026 |
In the US, the UK and Australia they are prescription-only medicines. The MHRA put it this way in July 2026: “As with all GLP-1 receptor agonists, this is a prescription-only medication”. Material sold as semaglutide for research use is none of these products. Peptide law by market: US, UK, Australia.
03What do the semaglutide labels warn about?
Boxed warning. All three US labels open with it: “In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures.” Whether it causes these tumours in humans, including medullary thyroid carcinoma, is unknown; the labels say their human relevance “has not been determined”. The medicines are contraindicated in people with a personal or family history of medullary thyroid carcinoma, or with Multiple Endocrine Neoplasia syndrome type 2.
Warnings. The Wegovy label (June 2026) lists acute pancreatitis, gallbladder disease, hypoglycaemia, acute kidney injury from fluid loss, severe gastrointestinal reactions, allergic reactions, diabetic retinopathy complications in type 2 diabetes, a raised heart rate, and pulmonary aspiration during anaesthesia or deep sedation. Acute pancreatitis, “including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists”. The most common adverse reactions are led by nausea, diarrhoea, vomiting, constipation and abdominal pain.
After approval. The Wegovy and Ozempic labels list reports of necrotizing pancreatitis “sometimes resulting in death”, intestinal obstruction, anaphylaxis and acute kidney injury; because such reports are voluntary, it is not always possible to estimate how often they happen or whether the drug caused them. In January 2026 the MHRA said the UK product information for all GLP-1 medicines had been updated on severe acute pancreatitis, “including rare reports of necrotising and fatal pancreatitis”. In February 2026 it said semaglutide “may be very rarely associated with” NAION, an eye condition that can cause vision loss, and that this “may affect up to 1 in 10,000 people taking semaglutide”. It cited a European review suggesting that in adults with type 2 diabetes semaglutide “may be associated with an approximately two-fold increase in the relative risk of developing NAION”; its expert advisers noted “conflicting evidence in the literature”.
In the trials. In SUSTAIN 6, retinopathy complications were more frequent with semaglutide than with placebo (hazard ratio 1.76). In SELECT, 16.6% of people on semaglutide stopped it for good because of adverse events, against 8.2% on placebo. How to read safety data: side effects, documented and unknown. To report one: report a reaction.
04Which trials stand behind the semaglutide labels?
Novo Nordisk funded each trial below. We give the design and what the label or paper reports for the primary measure.
| Trial and paper | Who took part, and for how long | Primary measure | What the label reports |
|---|---|---|---|
| SUSTAIN 6 · NEJM, 2016 | 3,297 adults with type 2 diabetes at high cardiovascular risk; semaglutide or placebo; 104 weeks | Cardiovascular death, non-fatal heart attack or non-fatal stroke; designed to show semaglutide was no worse than placebo | “Significantly reduced the occurrence” of these events; hazard ratio 0.74 (95% CI 0.58 to 0.95) |
| STEP 1 · NEJM, 2021 | 1,961 adults with obesity, or overweight with a weight-related condition, without diabetes; 2 to 1, semaglutide or placebo, both with a lifestyle programme; 68 weeks | Percentage change in body weight, and the share losing at least 5% | “A statistically significant reduction in body weight compared with placebo” (label, for this and two similar trials) |
| SELECT · NEJM, 2023 | 17,604 adults aged 45 or older with established cardiovascular disease and a BMI of 27 or more, without diabetes; mean follow-up 39.8 months | Cardiovascular death, non-fatal heart attack or non-fatal stroke | “Significantly reduced the risk”; hazard ratio 0.80 (95% CI 0.72 to 0.90) |
| FLOW · NEJM, 2024 | 3,533 adults with type 2 diabetes and chronic kidney disease; median 3.4 years, stopped early after a planned interim analysis | Kidney failure, a fall of at least 50% in kidney function, or death from kidney or cardiovascular causes | Hazard ratio 0.76 (95% CI 0.66 to 0.88) |
A hazard ratio below 1 means a lower event rate with semaglutide; each result holds for the people, product and follow-up studied. In STEP 1 and two similar weight trials, 6.8% of people on semaglutide and 3.2% on placebo stopped treatment because of an adverse reaction. How we grade evidence: evidence grades.
05What happened to compounded semaglutide in the US?
FDA limits compounded copies of an approved drug; the limits relax while the drug is on FDA’s shortage list. Semaglutide was listed from 2022. When the shortage ended, FDA set dates after which it would act on copies.
FDA: “the shortage of semaglutide injection products … is resolved”.
The end date for state-licensed pharmacies and physicians (section 503A), or a court ruling if later. The court denied a preliminary injunction on 24 April 2025, and FDA said the period “has ended”.
The end date for outsourcing facilities (section 503B).
FDA: “Tirzepatide and semaglutide do not currently appear on the 503B bulks list or on FDA’s drug shortage list.”
FDA on compounded semaglutide. Compounded drugs “are not FDA approved”, and FDA does not review them for safety, effectiveness or quality before they are sold. Salt forms such as semaglutide sodium and acetate “are different active ingredients than are used in the approved drugs”, and FDA is “not aware of any lawful basis for their use in compounding” (see peptide salt forms). By 31 May 2026 FDA had 990 adverse-event reports for compounded semaglutide. It says many resemble those for the approved versions, that the true number is likely higher because state-licensed pharmacies that are not outsourcing facilities do not have to report, and that “It is not always possible to determine if the adverse event directly resulted from use of the drug”. FDA has also received reports of adverse events, some requiring hospitalisation, that may relate to dosing errors. It also describes fraudulent compounded semaglutide labelled with pharmacies that do not exist or did not make it.
06What has FDA said about counterfeit and research-labelled semaglutide?
Counterfeits. FDA’s counterfeit Ozempic alert records seizures in the US drug supply chain in December 2023 (thousands of counterfeit products, with counterfeit needles whose sterility could not be confirmed), April 2025 (several hundred) and December 2025 (dozens). On 18 October 2023 the MHRA said products falsely labelled as Ozempic had been found at two UK wholesalers; all were recalled, and none had been supplied to UK patients.
Research-labelled semaglutide. FDA’s GLP-1 page (content current 1 October 2026) says the agency “has warned companies that have illegally sold unapproved drugs containing semaglutide, tirzepatide, retatrutide, survodutide or mazdutide that are falsely labeled ‘for research purposes’ or ‘not for human consumption’”, and says these products, sold directly to consumers, are “of unknown quality and may be harmful to their health”.
A lab report shows what one tested sample contained. It cannot make that sample Ozempic, Rybelsus or Wegovy. More: contamination and mislabeling. Semaglutide is also one of the two drugs in an investigational combination: cagrilintide and CagriSema.
07What we don’t know
- Whether semaglutide causes thyroid C-cell tumours in humans. The labels say the human relevance of the rodent finding “has not been determined”.
- What confirmatory evidence will show for MASH. The US approval is accelerated, “based on improvement of MASH and fibrosis”, and continued approval may depend on verifying clinical benefit; the EU and UK MASH approvals are conditional.
- Whether semaglutide causes NAION. The MHRA says it “may be very rarely associated with” NAION, and its expert advisers noted “conflicting evidence in the literature”.
- How it affects athletes. WADA kept the status of GLP-1 receptor agonists unchanged for 2027 “pending further data becoming available on the possible effects on athletes who take them”.
- What any product sold outside the licensed supply chain contains. FDA calls research-labelled semaglutide “of unknown quality”.
This is a plain-English summary of public documents and studies, checked on 18 Nov 2026. It is not legal or medical advice.